Clinical Biorepository Core

摘要 这种PPG应用的总体前提是在PPG的发展过程中存在共享的生物路径 COPD和IPF。为进一步了解慢性阻塞性肺疾病的流行病学、生物学和遗传学特点， IPF(对烟草烟雾等常见有害暴露的发散性肺反应) 从几个现有的COPD和IPF队列中收集和整理数据，并创建一个新的Bron- 胆道镜检查队列。该临床生物信息库核心将为所有合作伙伴提供统一的标准数据集 此应用程序中的调查人员。这些数据将包括临床、流行病学、生理学和放射学亚 分型信息以及将用于横断面和纵向分析的生物标本。 为了实现这些目标，临床生物信息库核心汇集了国际公认的 研究人员团队，其专业知识涵盖临床调查、放射学评估和支气管镜检查 学习。这项调查将利用的现有队列包括NIH资助的三个项目， COPDgene、SPIROMICS和肺组织研究联盟(LTRC)，每一个都有丰富的 将用于疾病亚型划分的表型数据。该核心还将利用由基金会资助的 这项工作被称为肺纤维化基金会临床护理注册和生物库(PFF)。最后， 未来的支气管镜检查人群将包括40名患有COPD的戒烟者(20名患有肺气肿 20名以呼吸道疾病为主的吸烟者)，30名患有IPF的前吸烟者(15名典型的UIP和15名 可能/不一致的UIP)和20名年龄和性别匹配的对照组(均为前吸烟者)。

ABSTRACT The overall premise of this PPG application is that there are shared biologic pathways in the development of COPD and IPF. To further understand the epidemiologic, biologic, and genetic characteristics of COPD and IPF (divergent pulmonary response to common noxious exposures such as tobacco smoke) we are proposing to aggregate and curate data from several existing COPD and IPF cohorts as well as create a de-novo bron- choscopy cohort. This Clinical Biorepository Core will provide a harmonized standard dataset for all co- investigators in this application. These data will include clinical, epidemiologic, physiologic and radiologic sub- typing information as well as biospecimens which will be used for cross sectional and longitudinal analyses. To achieve these goals, the Clinical Biorepository Core has brought together an internationally recognized team of investigators whose expertise spans clinical investigation, radiologic assessments and bronchoscopic studies. The existing cohorts to be leveraged by this investigation include three NIH funded projects, COPDGene, SPIROMICS and the Lung Tissue Research Consortium (LTRC), each of which has a wealth of phenotypic data that will be leveraged for disease subtyping. This Core will also leverage a foundation funded effort called the Pulmonary Fibrosis Foundation Clinical Care Registry and Biorepository (PFF). Finally, the prospective Bronchoscopy Population will include 40 ex-smoking subjects with COPD (20 with emphysema predominant and 20 with airway predominant disease), 30 ex-smokers with IPF (15 with Typical UIP and 15 with probable/inconsistent UIP) and 20 age and sex matched controls (all ex-smokers).